Physician profile
Cassandra Case
NPI 1952716086
$2,142.94
in general payments reported to CMS, 2019-2025
28 companies · $665 in 2025
The $665 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $202 · 2023: $254 · 2024: $799 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.97 | 2021-2025 | |
| Pfizer INC. | $250.56 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.78 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $179.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $156.46 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $156.31 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $140.28 | 2021-2025 | Evenity, Prolia, Repatha |
| Axsome Therapeutics, INC. | $53.88 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $49.44 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $44.64 | 2024-2025 | Mounjaro, Zepbound |
| Radius Health, INC. | $40.29 | 2023-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $40.13 | 2024-2025 | |
| Sanofi Pasteur INC. | $38.72 | 2023-2025 | |
| Glaxosmithkline, LLC. | $36.05 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Lundbeck LLC | $32.06 | 2022-2024 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $20.90 | 2025 | Austedo Xr |
| Astellas Pharma US INC | $20.85 | 2025 | Veozah |
| Abbott Laboratories | $19.28 | 2025 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $19.03 | 2025 | Aptima |
| Regeneron Healthcare Solutions, INC. | $18.50 | 2023 | Evkeeza |
| Xeris Pharmaceuticals, INC. | $16.86 | 2024 | Gvoke Hypopen |
| Corcept Therapeutics | $15.84 | 2024 | Korlym |
| Amarin Pharma, INC. | $15.38 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.23 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.78 | 2021 | |
| Merck Sharp & Dohme LLC | $11.97 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.